NCT04396717: Safety Study of Pritumumab in Brain Cancer

NCT04396717
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Phase 1
Drug Category: Therapeutic antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain, Leptomeningeal Disease
Additional Notes: 
Exclusions: 
https://ClinicalTrials.gov/show/NCT04396717

Comments are closed.

Up ↑